Product Description
Rhom2 controls the enzyme TACE, a key node in several disease-causing signaling pathways. Tested in vitro and in mouse models of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), these antibodies potently and selectively inhibit TACE in immune cells, thereby protecting against RA and IBD. By targeting iRhom2/TACE, the SciRhom antibodies simultaneously block several established signaling pathways that are currently targeted individually by drugs approved for autoimmune disorders, including TNF-alpha and IL-6R signaling. Superior efficacy, as demonstrated in preclinical proof-of-principle studies, and an expected favorable safety profile make anti-iRhom2 antibodies prime candidates to outperform standard of care. Four patent families secure exclusivity for anti-iRhom2 inhibitors and provide broad protection against follow-on drugs. Current leading indications in the company's development pipeline are RA, IBD, and lupus nephritis. (Sourced from: https://scirhom.com/)
Mechanisms of Action: IRhom2 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: SciRhom
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Blood Protein Disorders|Weight Gain|Inflammation
Phase 0: Autoimmune Disease Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06607484 |
SR-878-01-001 | P1 |
Terminated |
Weight Gain|Inflammation|Blood Protein Disorders |
2025-02-27 |
50% |
2025-06-04 |
Recent News Events
Date |
Type |
Title |
|---|